Medicine Overview

Indication

Know Medicine, Follow Guideline

Adult Dose

Clinical InformationAdministration Information
Indication: B-Cell Chronic Lymphocytic Leukemia
Age: Adult
Dose: Intravenous infusion – 25 mg/sq.meter
Frequency: once daily
Duration: 5 days
Note: infusion over 30 minutes; up to 30 mg/sq.meter; repeat every 28 days
Indication: B-Cell Chronic Lymphocytic Leukemia
Age: Adult
Dose: Oral – 40 mg/sq.meter
Frequency: once daily
Duration: 5 days
Note: repeat every 28 days

Child Dose

Clinical InformationAdministration Information
Age: Child
Dose: Tablet – Safety and efficacy not established
Note: Safety and efficacy not established

Renal Dose

Clinical InformationAdministration Information
Condition: Renal impairment Creatinine Clearance 30-70 mL/min
Dose: Dosage – Reduce by 20%
Note: Renal impairment
Condition: Renal impairment Creatinine Clearance less than 30 mL/min
Dose: Intravenous – Not recommended
Note: Renal impairment
Administration
  • For IV use only
  • Must be diluted before use
Side Effect

Drug Interaction

Drug NameRisk Factors
Pentostatin
Co-administration may lead to pulmonary toxicity
Cytarabine
Reduced metabolic activation of fludarabine

Disease Interaction

Disease NameRisk Factors
Severe renal impairment
Dangerous for patients with kidney problems (CrCl <30 mL/min)
Decompensated hemolytic anemia
Can worsen blood condition

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Refrigerate at 2-8° C

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.